Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,050 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Determining the sample size in a clinical trial.
Kirby A, Gebski V, Keech AC. Kirby A, et al. Med J Aust. 2002 Sep 2;177(5):256-7. doi: 10.5694/j.1326-5377.2002.tb04759.x. Med J Aust. 2002. PMID: 12197821 No abstract available.
Cost-effectiveness of cholesterol-lowering therapy with pravastatin in patients with previous acute coronary syndromes aged 65 to 74 years compared with younger patients: results from the LIPID study.
Tonkin AM, Eckermann S, White H, Friedlander D, Glasziou P, Magnus P, Kirby A, Mulray S, Denton M, Sallaberger M, Hunt D, Simes J; LIPID Study Group. Tonkin AM, et al. Among authors: kirby a. Am Heart J. 2006 Jun;151(6):1305-12. doi: 10.1016/j.ahj.2005.07.014. Am Heart J. 2006. PMID: 16781242 Clinical Trial.
Biomarkers in stable coronary heart disease, their modulation and cardiovascular risk: The LIPID biomarker study.
Tonkin AM, Blankenberg S, Kirby A, Zeller T, Colquhoun DM, Funke-Kaiser A, Hague W, Hunt D, Keech AC, Nestel P, Stewart R, Sullivan DR, Thompson PL, West M, White HD, Simes J; LIPID study investigators. Tonkin AM, et al. Among authors: kirby a. Int J Cardiol. 2015 Dec 15;201:499-507. doi: 10.1016/j.ijcard.2015.07.080. Epub 2015 Aug 16. Int J Cardiol. 2015. PMID: 26318511 Clinical Trial.
Long-Term Effectiveness and Safety of Pravastatin in Patients With Coronary Heart Disease: Sixteen Years of Follow-Up of the LIPID Study.
Hague WE, Simes J, Kirby A, Keech AC, White HD, Hunt D, Nestel PJ, Colquhoun DM, Pater H, Stewart RA, Sullivan DR, Thompson PL, West M, Glasziou PP, Tonkin AM; LIPID study investigators†. Hague WE, et al. Among authors: kirby a. Circulation. 2016 May 10;133(19):1851-60. doi: 10.1161/CIRCULATIONAHA.115.018580. Epub 2016 Mar 25. Circulation. 2016. PMID: 27016105 Review.
Circulating Cystatin C Is an Independent Risk Marker for Cardiovascular Outcomes, Development of Renal Impairment, and Long-Term Mortality in Patients With Stable Coronary Heart Disease: The LIPID Study.
West M, Kirby A, Stewart RA, Blankenberg S, Sullivan D, White HD, Hunt D, Marschner I, Janus E, Kritharides L, Watts GF, Simes J, Tonkin AM; LIPID Study Group *. West M, et al. Among authors: kirby a. J Am Heart Assoc. 2022 Mar;11(5):e020745. doi: 10.1161/JAHA.121.020745. Epub 2022 Feb 18. J Am Heart Assoc. 2022. PMID: 35179040 Free PMC article.
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins.
Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R; Cholesterol Treatment Trialists' (CTT) Collaborators. Baigent C, et al. Among authors: kirby a. Lancet. 2005 Oct 8;366(9493):1267-78. doi: 10.1016/S0140-6736(05)67394-1. Epub 2005 Sep 27. Lancet. 2005. PMID: 16214597
1,050 results